Almac launches biomarkers for biopharma
13 August 2010
Almac has launched a range of biomarkers for the biopharma industry.
The use of biomarkers enables biopharma companies to better understand
their drug, improve their drug’s success rate, improve the drug’s value
and ultimately maximise their drug’s potential.
Biomarkers can add substantial value to a compound in development
and the ability to identify those patients most likely to respond to
a therapy greatly increases the chances of success and the licensing
potential of the drug.
Biomarkers for biopharma solutions include pharmacodynamic
solutions, patient selection markers, assay development and
bioinformatics / biostatistics consultancy.
President and Managing Director of Almac’s Diagnostics division,
Professor Paul Harkin said: “With biomarkers for biopharma, we have
combined a range of key solutions which are ideally suited to
growing biopharma companies. For these companies, it is of critical
importance that they maximise the potential success of the drugs in
their pipeline and the incorporation of a biomarker strategy enables
them to do this.”